Go to deals
Healthcare

VivaSon Group has sold a minority stake to Korian

Korian has acquired a minority stake in VivaSon Group.

Korian is a French company specialized in nursing home care for the elderly. Listed on Euronext Paris, Korian has nursing homes in France, Germany, Belgium, Italy, Spain and the Netherlands.

Founded in 2006, VivaSon is a family group dedicated to the distribution of auditory prostheses through a network of approximately 30 points of sale in France. The company had a turnover of US$18 million in 2020.

Oaklins’ team in France acted as buy-side advisor in this transaction.

Parties

Talk to the deal team

Arnaud Dubois

Senior Advisor
Lyon, France
Oaklins France

Related deals

MEDIK Hospital Design Group has been acquired by STERIS
Construction & Engineering Services | Healthcare

MEDIK Hospital Design Group has been acquired by STERIS

The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.

Learn more
bioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Healthcare

bioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG

Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.

Learn more
SLT has been acquired by Indutrade
Healthcare

SLT has been acquired by Indutrade

SLT S.r.l. has been acquired by Indutrade AB and will be integrated into the group’s life science business area. The transaction is Indutrade’s fifth acquisition in 2025 and is expected to have a marginally positive impact on the group’s earnings per share.

Learn more